Express Scripts Eyeing Pricey Cancer Drugs Next

Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs.

"This is going to be a much slower and much bigger effort over time than what you saw for hepatitis," Steve Miller, chief medical officer of Express Scripts, told analysts during a conference call. "Cancer is different than any other disease, much more emotional."

Mr Miller said his company, the largest US pharmacy benefit manager, plans incremental moves and new tools to control cancer drug costs.

Read more at Reuters: http://reut.rs/1zhjXqP